Skip To Main Content
Enlivex Therapeutics on Muck Rack

Enlivex Therapeutics

As seen in: Olean Times Herald, The Salamanca Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Enlivex

Contact Enlivex, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method

|
By Enlivex Therapeutics
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method Nes-Ziona, Israel, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the U.S. Patent and Trademark Office issued a new patent, number US 11,883,429, covering AllocetraTM, the Company’s immunotherapy product candidate.
Open in Who Shared View Duplicates (25) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update

|
By Enlivex Therapeutics
| Research Pool
Enrollment of patients in the Phase I/II evaluating Allocetra™ in combination with chemotherapy in patients with peritoneal metastases from advanced solid tumors is proceeding as planned, with 50% (lower dose cohorts) already enrolled.
Open in Who Shared View Duplicates (34) Issue with article?

GlobeNewsWire - Enlivex Therapeutics (ENLV) Enlivex to Present at the 2023 Jefferies Healthcare Conference

|
By Enlivex Therapeutics
| Research Pool
Nes-Ziona, Israel, June 06, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will present a corporate update at the 2023 Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York, NY. The presentation will take place on June 9, 2022, at 11:30 AM Eastern Time. A webcast of the presentation will be available at , and will be archived for 90 days.
Open in Who Shared View Duplicates (128) Issue with article?
See all 45 articles